| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5154281 | B | Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21(DE3) using Dabcyl-KLSAVLQSGERKM-Edans as substrate at 5 uM incubated for 30 mins followed by substrate addition by FRET assay | Severe acute respiratory syndrome coronavirus 2 | 3 | assay format | Scientific Literature | ||
| 2. | ALA5154282 | B | Inhibition of SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) using CBZ-RLRGG-AMC as substrate at 5 uM incubated for 30 mins followed by substrate addition by FRET assay | Severe acute respiratory syndrome coronavirus 2 | 3 | assay format | Scientific Literature | ||
| 3. | ALA5154283 | B | Binding affinity to SARS-CoV-2 MPro expressed in Escherichia coli BL21(DE3) assessed as mass shift at 15 uM incubated for 4 hrs by mass spectrometry analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 4. | ALA5154284 | B | Binding affinity to SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) assessed as mass shift at 30 uM incubated for 4 hrs by mass spectrometry analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 5. | ALA5154285 | A | Drug metabolism in normal saline assessed as conversion of closed form to open form by measuring rate constant at equilibrium at 2 mg/ml measured at 5 hrs by RP-HPLC analysis | 1 | assay format | Scientific Literature | |||
| 6. | ALA5154286 | B | Covalent binding affinity to Cys145 residue of SARS-CoV-2 MPro expressed in Escherichia coli BL21(DE3) assessed as trypsin digestion mediated mass shift by mass spectrometry analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 7. | ALA5154287 | B | Covalent binding affinity to Cys111 residue of SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) assessed as mass shift at 3 to 15 uM incubated for 4 hrs followed by trypsin digestion by mass spectrometry analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 8. | ALA5154288 | B | Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21(DE3) using Dabcyl-KLSAVLQSGERKM-Edans as substrate assessed as inhibition constant measured for 30 mins by fluorimetry based microplate reader analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 9. | ALA5154289 | B | Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21(DE3) using Dabcyl-KLSAVLQSGERKM-Edans as substrate assessed as inactivation constant measured for 30 mins by fluorimetry based microplate reader analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 10. | ALA5154290 | B | Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21(DE3) using Dabcyl-KLSAVLQSGERKM-Edans as substrate assessed as Kinact/Ki measured for 30 mins by fluorimetry based microplate reader analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 11. | ALA5154291 | B | Inhibition of SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) using CBZ-RLRGG-AMC as substrate assessed as inhibition constant measured for 30 mins by fluorimetry based microplate reader analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 12. | ALA5154292 | B | Inhibition of SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) using CBZ-RLRGG-AMC as substrate assessed as inactivation constant measured for 30 mins by fluorimetry based microplate reader analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 13. | ALA5154293 | B | Inhibition of SARS-CoV-2 PLpro expressed in Escherichia coli BL21(DE3) using CBZ-RLRGG-AMC as substrate assessed as Kinact/Ki measured for 30 mins by fluorimetry based microplate reader analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 14. | ALA5154294 | B | Binding affinity to SARS-CoV-2 MPro C145A mutant assessed as dissociation constant by isothermal titration calorimetry assay | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 15. | ALA5154295 | B | Binding affinity to SARS-CoV-2 PLpro C111A mutant assessed as dissociation constant by isothermal titration calorimetry assay | Severe acute respiratory syndrome coronavirus 2 | 1 | assay format | Scientific Literature | ||
| 16. | ALA5154296 | B | Inhibition of human PAK2 at 1 uM by DiscoverX KINOMEscan assay relative to control | Homo sapiens | 1 | single protein format | Scientific Literature | ||
| 17. | ALA5154297 | B | Inhibition of human PIM1 at 1 uM by DiscoverX KINOMEscan assay relative to control | Homo sapiens | 1 | single protein format | Scientific Literature | ||
| 18. | ALA5154298 | B | Inhibition of native full length human thrombin using Boc-Asp(OBz1)-Pro-Arg-AMC as substrate at 5 uM incubated for 30 mins followed by substrate addition by fluorescence based analysis | Homo sapiens | 1 | single protein format | Scientific Literature | ||
| 19. | ALA5154299 | B | Inhibition of native full length human factor 10a using Bz-Ile-Glu-Gly-Arg-pNA as substrate at 5 uM incubated for 30 mins followed by substrate addition by fluorescence based analysis | Homo sapiens | 1 | single protein format | Scientific Literature | ||
| 20. | ALA5154300 | B | inhibition of native full length human plasmin using H-D-Val-Leu-Lys-pNA as substrate at 5 uM incubated for 30 mins followed by substrate addition by fluorescence based analysis | Homo sapiens | 1 | single protein format | Scientific Literature |
The page will load shortly, Thanks for your patience!